One of the most common knocks against index funds is that they guarantee you average returns minus fees and, by golly, clients need above average returns or else they're going to start looking for a new adviser.
But it's silly to think that the only way an adviser can add alpha to a client's portfolio is by finding the next hot fund manager, sector or stock.
In fact, for advisers, adding alpha is as simple as making savvy tax moves and as stopping clients from making classic investing mistakes like buying high, selling low and thinking short-term instead of long-term. These are all basic things that mom-and-pop investors probably aren't thinking about on their own. And these are things that an adviser can actually control, unlike, say, the market's returns.
10 Best Financial Stocks To Buy For 2015: AEterna Zentaris Inc.(AEZS)
Aeterna Zentaris Inc. operates as a late-stage drug development company specialized in oncology and endocrine therapy. Its lead oncology compounds include perifosine, a PI3K/Akt pathway inhibitor that is in Phase 3 registration trial for refractory advanced colorectal cancer and multiple myeloma; and AEZS-108, a doxorubicin-targeted conjugate in Phase II for the treatment of ovarian, endometrial, castration refractory prostate, and refractory bladder cancer. The company?s lead endocrinology compound, AEZS-130, is an oral ghrelin antagonist in Phase III trial as a diagnostic test for adult growth hormone deficiency. Its pipeline also includes earlier-stage compounds, such as AEZS-112 that is in a Phase I trial in advanced solid tumors and lymphoma, as well as AEZS-120, an anti-cancer vaccine in pre-clinical development. The company was founded in 1991 and is headquartered in Quebec City, Canada.
Advisors' Opinion:- [By Sean Williams]
What's coming down the pipeline
Avastin: Surprise: It's Roche's (NASDAQOTH: RHHBY ) wonder drug yet again! Roche's Avastin is in the process of being tested as a treatment for recurrent endometrial cancer and demonstrated promising results in a mid-stage trial according to the Journal of Clinical Oncology. Avastin, which is an angiogenesis inhibitor (a fancy way of saying it inhibits blood vessel growth), was tested on 52 evaluable patients and delivered a progression-free survival of at least six months for 21 of them. Overall median PFS was 4.2 months, and median overall survival came in at 10.5 months. Don't be surprised if Roche decides to pursue further studies of Avastin in recurrent endometrial cancer with these results.� AEZS-108: Currently in late-stage development by Aeterna Zentaris (NASDAQ: AEZS ) , a holding in my own portfolio, AEZS-108 is an intravenous treatment composed of a synthetic peptide carrier and doxorubicin that targets Luteinizing Hormone Releasing Hormone-receptor expressing tumors. That series of scientific jargon simply means it targets cancer cells with minimal healthy cell death relative to the current standards of treatment. In mid-stage trials, AEZS-108 delivered an overall response rate of 30.8% and a clinical benefit rate of 74.4%. These figures were enough to get AEZS-108 a special protocol assessment (SPA), which should streamline its approval if these results stay consistent in late-stage studies.
As we saw with the current treatment options, the endometrial cancer pipeline isn't filled with a lot of choices, but they are at least more encouraging than the standard care treatments we've seen over the past three decades.Your best investment
With very few investable options to choose from, since many of these treatments are off patent as they're decades old, I'm going to split my decision this week between Roche and Aeterna Zentaris for obvious reasons. - [By Roberto Pedone]
Aeterna Zentaris (AEZS), a specialty biopharmaceutical company, is focused on developing and commercializing novel treatments in oncology and endocrinology. This stock closed up 5% to $1.25 in Thursday's trading session.
Thursday's Range: $1.19-$1.26
52-Week Range: $0.99-$1.75
Thursday's Volume: 1.32 million
Three-Month Average Volume: 646,050From a technical perspective, AEZS ripped sharply higher here right above its 50-day moving average of $1.17 and back above its 200-day moving average of $1.22 with strong upside volume flows. This sharp spike higher on Thursday also pushed shares of AEZS into breakout territory, since the stock took out some more near-term overhead resistance at $1.23. This move is starting to push shares of AEZS within range of triggering another big breakout trade. That trade will hit if AEZS manages to take out some key overhead resistance levels at $1.28 to $1.35 with high volume.
Traders should now look for long-biased trades in AEZS as long as it's trending above its 200-day at $1.22 or above Thursday's intraday low of $1.19 and then once it sustains a move or close above those breakout levels with volume that hits near or above 646,050 shares. If that breakout begins soon, then AEZS will set up to re-test or possibly take out its next major overhead resistance levels at $1.52 to $1.62.
- [By Eric Volkman]
Aeterna Zentaris (NASDAQ: AEZS ) has made a significant change in its executive suite and boardroom. David Dodd is now the company's chief executive and a member of its board of directors. He succeeds Juergen Engel. The firm did not provide the reasons for the succession.
- [By Sean Williams]
High-risk, high-reward suggestions
Exelixis (NASDAQ: EXEL ) : In November Exelixis had its first drug, known as Cometriq, approved by the Food and Drug Administration to treat metastatic medullary thyroid cancer. Although the market for this disease is pretty small -- somewhere between 500 and 700 people in the U.S. -- the near-tripling in progression-free survival, or PFS, in trials would indicate to me a strong likelihood that it could translate to success in other cancer types. In mid-stage prostate cancer trials, for instance, Cometriq was found to be particularly effective in dealing with bone metastases as a second or third-line treatment. We won't get any additional data until next year on Cometriq, but positive data on the prostate cancer front could be enough to double its share price if the PFS, compared to the placebo, is notably strong. ImmunoGen (NASDAQ: IMGN ) : In February, Roche�and ImmunoGen received approval for Kadcyla as a secondary treatment for HER2-positive breast cancer. This is ImmunoGen's first drug approval, and it gives the company a chance to showcase what I feel is one of the future pathways of fighting cancer -- its targeted-antibody payload, or TAP, technology. ImmunoGen's TAP technology works by attaching a toxin -- in this case Roche's Herceptin -- to an antibody, and teaching that antibody to release the to
There's an undeniably large dollar amount being pledged to cancer research, but, even if a drug gains approval, that's no guarantee that the biotech or pharmaceutical company behind that drug will be a success. Some of the biggest gains (and losses) come from taking a leap of faith based on clinical data, or the approval of one or two drugs or devices within a pipeline. After that, it's all up to the drug or devices' effectiveness, its pricing, and the success of the marketing teams promoting the drug or device. Here are a few high-risk, high-reward names you should be keeping your eye on.
Top 10 Managed Healthcare Stocks To Own Right Now: Dj Wilshire Reit Etf (RWR)
SPDR DJ Wilshire REIT (the Fund), formerly DJ Wilshire REIT ETF, seeks to replicate as closely as possible the performance of the Dow Jones Wilshire REIT Index (the Index). The Fund utilizes a passive or indexing approach, and attempts to approximate the investment performance of its Index, by investing in a portfolio of stocks to replicate the Index. The Index seeks to provide an effective representation of the United States real estate investment trust (REIT) market.
The Index consists of companies whose charters are the equity ownership and operation of commercial real estate, and which operate under the REIT Act of 1960. The Index is generally rebalanced monthly. Companies are chosen based upon market capitalization, source of revenue and liquidity. Each REIT in the Index is weighted by its float-adjusted market capitalization. The Fund�� investment manager is SSgA Funds Management, Inc.
Advisors' Opinion:- [By Chuck Saletta]
Where to invest?
Domestic stocks. The Vanguard Total Market (NYSEMKT: VTI ) ETF is a one-stop-shop that gives you access to around 99.5% by market cap of the publicly held U.S. stocks traded on major exchanges. A mere 3% turnover and microscopically low 0.05% expense ratio makes this a low-cost way to invest in the overall stock market. Investment-grade bonds. The iShares iBoxx $Invest Grade Corp Bond � (NYSEMKT: LQD ) ETF owns nearly $24 billion worth of investment-grade corporate bonds. A small 4% turnover and low 0.15% expense ratio make this a low-cost way to get bond exposure. Real estate. The SPDR Dow Jones REIT (NYSEMKT: RWR ) ETF has a bit over $2 billion invested in real estate investment trusts, attempting to match the Dow Jones Select REIT index. With a reasonable 7% turnover and a still pretty low 0.25% expense ratio, this is a reasonable way to get real estate exposure without turning yourself into a landlord. Foreign stocks. Vanguard's Total International Stock Index (NASDAQ: VXUS ) ETF has nearly $90 billion in foreign stocks under its control, owning pieces of more than 6,100 stocks from 45 countries. With a mere 3% turnover and low 0.16% expense ratio, it's one of the lowest-cost ways to get your hands on foreign companies without being an international accounting expert. Inflation-protected government bonds. The iShares Barclays TIPS Bond (NYSEMKT: TIP ) ETF has around $20 billion invested in U.S. Treasury inflation-protected bonds. With a low expense ratio of 0.2% and a reasonable 10% turnover rate, it's a decent way to get exposure to inflation-protected bonds. Note, though, that
There are countless possibilities for building your retirement portfolio to cover Social Security's gap, depending on your personal risk tolerance, timeline, and need for cash. Here are decent index-style ETFs across various asset types to consider when building your plan: - [By Hilary Kramer]
2. Real Estate Investment Trusts (REITs) The REIT is another alternative vehicle that's gone mainstream in recent years. Hundreds of broad-based and specialized real estate companies and ETFs are available, and after a correction a few months ago, many are on the cheap side. Like any other alternative, this should be a seasoning for your portfolio and not the sauce itself. For most retail investors, a stake in an indexed fund like the SPDR Dow Jones REIT (NYSE: RWR) should be more than adequate, or look into the companies that provide services to the REIT industry like HFF (NYSE: HF) and Jones Lang LaSalle (NYSE: JLL).
Top 10 Managed Healthcare Stocks To Own Right Now: j2 Global Inc (JCOM)
j2 Global, Inc., incorporated on December 14, 1995, is a provider of services delivered through the Internet. The Company provides cloud services to businesses of all sizes, from individuals to enterprises. The Company operates in two segments: Business Cloud Services and Digital Media. The Company's Digital Media business segment consists of the Web properties and business operations of Ziff Davis, Inc. (Ziff Davis). The Company�� cloud services and solutions include fax, voice and unified communications, email and customer relationship management, online backup, global network and operations, and customer support services. In February 2013, it acquired IGN Entertainment, Inc. On November 9, 2012, the Company acquired Ziff Davis. Effective March 18, 2013, it acquired MetroFax Inc. In April 2013, the Company acquired Backup Connect BV.
Business Cloud Services
The Company's eFax and MyFax online fax services enable users to receive faxes into their email inboxes and to send faxes via the Internet. eVoice and Onebox provides the Company's customers a virtual phone system with various available enhancements. The Company's FuseMail service provides the Company's customers email, archival and perimeter protection solutions, while Campaigner provides its customers email marketing solutions. KeepItSafe enables the Company's customers to securely backup their data and dispose of tape or other physical systems. The Company's CampaignerCRM business provides customer relationship management solutions designed to increase the Company's customers' sales and increase efficiency. The Company also generates Business Cloud Services revenues from patent licensing and sales and advertising. The Company�� Business Cloud Services and solutions are of two types: direct inward-dial number (DID) -based, which are services provided in whole or in part through a telephone number and non-DID-based, which are its other cloud services for business. As of December 31, 2012, the Company had DIDs issued! to approximately 2.1 million paying subscribers.
The Company's services allow individuals to receive and send faxes as email attachments. In addition to eFax , the Company offers online fax services under a variety of alternative brands, including MyFax , eFax Plus , eFax Pro, eFax Corporate and eFax Developer . eVoice is a virtual phone system that provides small and medium-sized businesses on-demand voice communications services, featuring a toll-free or local company DID, auto-attendant and menu tree. With these services, a subscriber can assign departmental and individual extensions that can connect to multiple United States or Canadian DIDs, including land-line and mobile phones and Internet protocol (IP) networks. These services also include advanced integrated voicemail for each extension, unifying mobile, office and other separate voicemail services and improving efficiency by delivering voicemails in both native audio format and as transcribed text. Onebox is a unified communications suite. It combines the features of many of the Company's other branded services, plus added functionality, to provide a virtual office. Onebox includes a virtual phone system, hosted email, online fax, audio conferencing and Web conferencing.
FuseMail offers hosted email, email encryption and email archival services to businesses. These solutions are hosted offsite and seamlessly integrated into a customer's existing email system. The services include hosted email, VirusSMART virus scanning, CypherSMART encryption services, SpamSMART SPAM filtering and VaultSMART / PolicySMART archiving, which delivers a secure, scalable email archiving and customizable compliance tool to correspond with a company's retention policy. Campaigner is an email marketing service that enables businesses to easily create and send personalized one-to-one email communications to subscribers and customers to build better relationships. Campaigner also helps businesses increase the size of their mailing lists, compl! y with em! ail regulations like CAN-SPAM and get more emails to more inboxes. CampaignerCRM is a cloud-based CRM solution specifically designed to help small/medium-sized businesses close more deals, reduce the sales cycle and sell larger deals. CampaignerCRM has a sales checklist capability that gives sales representatives a step-by-step plan to closing a deal. With CampaignerCRM's Social CRM capabilities, companies can seamlessly integrate a customer's latest information from Twitter, LinkedIn, and Facebook directly into their Contact profile. KeepItSafe provides managed and monitored online backup solutions for businesses, using its ISO-certified platform.
The Company's Business Cloud Services business operates multiple physical Points of Presence (POPs) worldwide, a central data center in Los Angeles and several remote disaster recovery facilities. The Company connects its POPs to its central data centers through redundant, and often times diverse, Virtual Private Networks (VPNs) using the Internet. The Company's network is designed to deliver value-added user applications, customer support and billing services for the Company's customers anywhere in the world and a local presence for its DID-based service customers from thousands of cities in 49 countries on six continents. The Company offers DIDs covering all major metropolitan areas in the United States, United Kingdom and Canada, and such other major cities as Berlin, Hong Kong, Madrid, Manila, Mexico City, Milan, Paris, Rome, Singapore, Sydney, Taipei, Tokyo and Zurich. The Company has customers located throughout the world.
The Company's Business Cloud Services customer service organization supports the Company's cloud services customers through a combination of online self-help, email communications, interactive chat sessions and telephone calls. The Company's Internet-based online self-help tools enable customers to resolve simple issues on their own, eliminating the need to speak or write to the Company's customer service re! presentat! ives. The Company's Business Cloud Services segment customer service organization provides email support seven days per week, 24 hours per day to all subscribers. Paying subscribers have access to live-operator telephone support seven days per week, 24 hours per day. Dedicated telephone support is provided for corporate customers 24 hours per day, seven days per week. Live sales and customer support services are available in nine languages, including English, Spanish, Dutch, German, French and Cantonese.
Digital Media
The Ziff Davis portfolio of Web properties, including PCMag.com, ExtremeTech.com, Geek.com, ComputerShopper.com, LogicBuy.com and Toolbox.com features reviews of technology products, technology-oriented news and commentary, professional networking tools for IT professionals and online deals and discounts for consumers. The Company generates Digital Media revenues from the sale of display advertising targeted to in-market technology buyers and from the sale of customer leads to online merchants and business-to-business leads to IT vendors. During the year ended December 31, 2012, Digital Media Web properties attracted 345 million visits and 1.1 billion page views.
PCMag is a trusted online resource for laboratory-based product reviews, technology news and buying guides. Toolbox.com is a network of online communities that allows experienced technology professionals to share collective knowledge and collaborate to resolve problems more efficiently. Toolbox.com includes professional networking tools, blogs, collaboration tools and reference guides. Geek.com is an online technology resource and community for technology enthusiasts and professionals. Its gaming site includes IGN.com and men's lifestyle site includes AskMen.com.
The Company competes with Google AdSense, DoubleClick Ad Exchange, AOL's Ad.com and Microsoft Media Network.
Advisors' Opinion:- [By Rich Smith]
j2 Global (NASDAQ: JCOM ) just keeps on growing -- by acquisition.
In its third corporate purchase in the past three months, j2 announced this morning that it has acquired Netherlands-based Backup Connect BV, a provider of online data backup services.
Top 10 Managed Healthcare Stocks To Own Right Now: Furiex Pharmaceuticals Inc (FURX)
Furiex Pharmaceuticals, Inc. is a drug development collaboration company. The Company�� product pipeline includes two marketed products and three programs in development, including late-stage compounds, in multiple therapeutic areas. Its programs include Priligy, Alogliptin Nesina, Alogliptin/Actose Combination, Alogliptin/Metformin Combination, Fluoroquinolone, Mu Delta and PPD 10558. In November 2011, it acquired full exclusive license rights to develop and commercialize the compound MuDelta under its existing development and license agreement with Janssen Pharmaceutica N.V.
Priligy (dapoxetine) is a drug developed for the on-demand treatment of premature ejaculation (PE). Dapoxetine is a short-acting, selective serotonin reuptake inhibitor (SSRI) designed to be taken only when needed one to three hours before sexual intercourse is anticipated rather than every day. Nesina (alogliptin) is a drug for the oral treatment of type 2 diabetes (T2D). Alogliptin is a DPP-4 inhibitor that slows the inactivation of incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP).
Fluoroquinolone drug candidate is a Phase II-ready novel fluoroquinolone antibiotic that is being developed by the Company for the treatment of complicated skin and skin structure infections, such as abscesses that occur deep in the skin layers and respiratory infections. This antibiotic has a spectrum of activity and is able to treat methicillin-resistant staphylococcus aureus (MRSA) infections. The Company is developing both oral and intravenous (IV) formulations. The Company is developing Mu Delta for treatment of diarrheal predominant irritable bowel syndrome (d-IBS). The Company is conducting a Phase II study on an oral formulation of Mu Delta.
The Company is developing PPD 10558 for the treatment of dyslipidemia. PPD 10558 has shown muscle safety in preclinical studies by minimizing the delivery of the drug to the muscle. The Company has filed an inve! stigational new drug (IND) application with the United States Food and Drug Association and completed five clinical studies.
Advisors' Opinion:- [By Lauren Pollock var popups = dojo.query(".socialByline .popC"); popups.forEach]
Forest Laboratories Inc.(FRX) agreed to acquire Furiex Pharmaceuticals(FURX) in a deal worth up to $1.33 billion that expands Forest Labs’ presence in gastroenterology. Furiex surged 28% to $102.21 premarket.
- [By Jake L'Ecuyer]
Top Headline
Forest Laboratories (NYSE: FRX) announced its plans to buy Furiex Pharmaceuticals (NASDAQ: FURX) for up to $1.46 billion. Forest will pay around $95 per share, or around $1.1 billion in cash. Forest Labs will also pay up to $30 per share, or around $360 million in a contingent value right. The deal is projected to close in the second or third quarter of 2014. - [By Michael Calia]
Furiex Pharmaceuticals Inc.(FURX) said its treatment for diarrhea-predominant irritable bowel syndrome showed simultaneous improvements in stool consistency and abdominal pain in two Phase III studies. The drug developer’s shares surged 78% to $82 in recent premarket trading.
Top 10 Managed Healthcare Stocks To Own Right Now: SVB Financial Group(SIVB)
SVB Financial Group, a diversified financial services company, provides various banking and financial products and services. The company offers deposit products, such as traditional deposit and checking accounts, certificates of deposit, money market accounts, and sweep accounts, as well as lockbox and merchant services; and lending products and services, including traditional term loans, equipment loans, asset-based loans, revolving lines of credit, accounts-receivable-based lines of credits, capital call lines of credits, and credit cards. It also provides cash management products and services comprising wire transfer and automated clearing house payment services, collection services, disbursement services, electronic funds transfers, and online banking services. In addition, the company offers foreign exchange services; letters of credit, including export, import, and standby letters of credit; investment services and solutions; brokerage; asset management; investment a dvisory services, such as outsourced treasury services; and non-banking products and services, such as funds management, venture capital/private equity investment, and equity valuation services. Further, it provides private banking services comprising mortgages, home equity lines of credit, restricted stock purchase loans, and other secured and unsecured lending services. As of March 09, 2012, the company operated 26 offices in the United States and 7 offices internationally. It serves customers in the technology, venture capital/private equity, life science, wine, and clean tech industries. The company was founded in 1982 and is headquartered in Santa Clara, California.
Advisors' Opinion:- [By Lisa Levin] Related ZU Benzinga's Top #PreMarket Losers Stocks Hitting 52-Week Lows Zulily Falls 30% on Earnings (Fox Business) Related SIVB SVB Financial Plans New Stock Offering - Analyst Blog Why SVB Financial (SIVB) Could Beat Earnings Estimates Again - Tale of the Tape
zulily (NASDAQ: ZU) shares moved up 9.65% to $35.10. The volume of zulily shares traded was 1005% higher than normal. Zulily's trailing-twelve-month revenue is $806.58 million.
- [By Will Ashworth]
While airlines have their ups and downs, Copa is about the best I can think of to weather the storm.
Best Stocks #4 (Midcap): SVB Financial (SIVB)
I never would have thought one of my picks for the next 20 years would be a bank — let alone one that focuses on entrepreneurs — but here I am.
- [By John Maxfield]
Given that you clicked on this article, it seems safe to assume you either own stock in SVB Financial (NASDAQ: SIVB ) or are considering buying shares in the near future. If so, then you've come to the right place. The table below reveals the nine most critical numbers that investors need to know about SVB Financial stock before deciding whether to buy, sell, or hold it.
Top 10 Managed Healthcare Stocks To Own Right Now: Blue Water Global Group Inc (BLUU)
Blue Water Global Group, Inc. (Blue Water), incorporated on March 3, 2011, is a development-stage company. The Company focuses on developing a chain of casual dining restaurants in tourist destinations throughout the Caribbean region. The Company's initial restaurant is going to be called Blue Water Bar & Grill and will be located in St. Maarten, Dutch West Indies.
As of February 7, 2013, the Company did not operate any restaurant properties, and did not have any ownership or leaseholds in any restaurant properties. As of February 7, 2013, the Company did not have any ownership or leaseholds in any restaurant properties.
Advisors' Opinion:- [By Peter Graham]
Small cap stocks Caribbean International Holdings (OTCMKTS: CIHN), Blue Water Global Group Inc (OTCBB: BLUU) and Metrospaces Inc (OTCMKTS: MSPC) have been getting some attention lately in various investment newsletters and all three have focused their activities in the Caribbean or South America. However, all three have been the subject of paid promotions which have helped to get them mentions in various investment newsletters. With that in mind, will bets on the Caribbean or South America pay off big for these three small cap stocks and their investors? Here is a quick reality check:
- [By Peter Graham]
Small cap stocks Naturalnano Inc (OTCMKTS: NNAN), Global Payout, Inc (OTCMKTS: GOHE) and Blue Water Global Group Inc (OTCBB: BLUU) were either jumping higher or diving lower yesterday. To complicate matters for investors, two of these small cap stocks have been subjects of disclosures about paid promotion or investor relation campaigns. So what will these three small caps do for the rest of this week? Here is a closer look to help you decide on a trading or investing strategy:
- [By Peter Graham]
Last Friday, small cap Digital Brand Media & Marketing Group Inc (OTCMKTS: DBMM) surged 22.22% while Blue Water Global Group Inc (OTCBB: BLUU) sank 18.42% and Medina International Holdings, Inc (OTCMKTS: MIHI) sank 50%. However, one of these small caps (Blue Water Global Group) appears to be reversing course in early morning trading today. So with it and the rest of these small cap stocks either sink or swim in trading this week? Here is a closer look to help you decide on an investing or trading strategy:
Top 10 Managed Healthcare Stocks To Own Right Now: PRGX Global Inc.(PRGX)
PRGX Global, Inc., together with its subsidiaries, provides recovery audit, healthcare claims recovery audit, and analytics and advisory services. The company?s recovery audit services are based on the mining and auditing of clients? purchasing data for overpayments to suppliers; and healthcare claims recovery audit services consist of identification of overpayments and underpayments made to healthcare providers, such as hospitals and physicians? practices. Its analytics and advisory services focuses on client functional and process areas and provides services to senior finance executives to optimize working capital, reduce enterprise costs, transform the finance function, and enhance corporate performance. The company serves retailers, such as discount, department, specialty, grocery, and drug stores; business enterprises, including manufacturers, financial services firms, and pharmaceutical companies; private sector health insurance companies, and state and federal go vernment payers consisting of the centers for Medicare and Medicaid Services; and federal and state government agencies. It has operations in the United States, Canada, rest of Latin America, Europe, Asia, and rest of the Pacific region. The company was formerly known as PRG-Schultz International, Inc. and changed its name to PRGX Global, Inc. in January 2010. PRGX Global, Inc. was founded in 1990 and is based in Atlanta, Georgia.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on PRGX Global (Nasdaq: PRGX ) , whose recent revenue and earnings are plotted below.
No comments:
Post a Comment